8-K: SELLAS Life Sciences Announces Positive Clinical Trial Updates and Secures $21 Million in Funding

SELLAS Life Sciences reported positive preliminary data from its SLS009 trial in AML, secured $21 million in funding, and received a recommendation to continue its Phase 3 REGAL study.

Summary

• SELLAS Life Sciences announced its financial results for the second quarter of 2024, reporting a net loss of $7.5 million, or $0.13 per share.
• The company's research and development expenses were $5.2 million for the quarter, down from $5.9 million in the same period last year.
• General and administrative expenses were $2.4 million, compared to $3.1 million in the second quarter of 2023.
• SELLAS reported a cash position of $9.1 million as of June 30, 2024, and subsequently raised $21 million through a registered direct offering.
• The company's Phase 2a trial of SLS009 in relapsed/refractory AML showed an overall response rate of 33% and 50% in the 60 mg QW and 30 mg BIW cohorts, respectively.
• Notably, the 30 mg BIW cohort with ASXL1 mutations achieved a 100% overall response rate.
• The Independent Data Monitoring Committee (IDMC) recommended the continuation of the Phase 3 REGAL study of galinpepimut-S (GPS) in AML without modifications, with an interim analysis expected in Q4 2024.
• SLS009 received Orphan Drug Designations from the EMA for AML and PTCL, and Rare Pediatric Disease Designations from the FDA for pediatric AML and ALL.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial results, regulatory designations, and a successful capital raise. The strong response rates in the SLS009 trial, particularly in the ASXL1 mutation cohort, are very encouraging. While there is a net loss, the overall tone is optimistic.

Positives

• The Phase 2a trial of SLS009 showed promising early signs of efficacy, with an overall response rate exceeding the targeted 20%.
• The 100% overall response rate in the ASXL1 mutation cohort of the SLS009 trial is a significant positive.
• The IDMC's recommendation to continue the Phase 3 REGAL study without modifications indicates confidence in the trial's progress.
• The $21 million capital raise strengthens the company's financial position and provides resources for upcoming data readouts.
• The regulatory designations for SLS009 from both the EMA and FDA highlight the potential of the drug.

Negatives

• The company reported a net loss of $7.5 million for the second quarter of 2024.
• The company's cash position was $9.1 million as of June 30, 2024, which may require further capital raises in the future.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to oncology product development and regulatory approval.
• The actual results and timing of events could differ materially from those anticipated in the forward-looking statements.
• The company's financial position may require additional capital raises in the future.

Future Outlook

The company anticipates the interim analysis of the Phase 3 REGAL study in Q4 2024 and expects to report initial safety and efficacy data from the PIVOT program in pediatric tumors throughout the second half of 2024.

Management Comments

• Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, stated that they are pleased with their second-quarter performance marked by significant advancements in their development efforts and clinical programs.
• Dr. Stergiou noted that the initial Phase 2a dataset from the SLS009 trial in AML showed early signs of treatment efficacy across all cohorts exceeding the targeted ORR of at least 20% and median overall survival (mOS) of more than 3 months.
• Dr. Stergiou also mentioned that the recent $21 million capital raise strengthens their financial position and provides sufficient resources to reach several meaningful data readouts.
• Dr. Stergiou expressed confidence in the positive trajectory of both GPS and SLS009 and looks forward to the interim results from the Phase 3 REGAL study, as well as additional data from the Phase 2 trial of SLS009 in AML.

Industry Context

This announcement is significant in the context of the biopharmaceutical industry, particularly in the development of novel cancer therapies. The positive data from the SLS009 trial and the progress of the REGAL study position SELLAS as a notable player in the field of AML treatment. The regulatory designations also highlight the potential of their drug candidates.

Comparison to Industry Standards

• The reported overall response rate (ORR) of 33% and 50% in the SLS009 trial for relapsed/refractory AML is promising when compared to standard treatments, which often have lower response rates.
• The 100% ORR in the ASXL1 mutation cohort is particularly noteworthy, as this patient population typically has a poor prognosis and limited treatment options.
• The median overall survival (mOS) of 5.4 months in the 45 mg QW safety dose cohort of SLS009, compared to 2.5 months with standard of care, suggests a potential improvement in patient outcomes.
• Companies like Agios Pharmaceuticals (AGIO) and Kura Oncology (KURA) are also developing therapies for AML, but SELLAS's approach with a CDK9 inhibitor and an immunotherapeutic offers a differentiated strategy.
• The regulatory designations for SLS009, including Orphan Drug and Rare Pediatric Disease Designations, are similar to those sought by other companies in the rare disease space, such as BioMarin Pharmaceutical (BMRN) and Ultragenyx Pharmaceutical (RARE).

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results and successful capital raise favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with AML and other cancers may benefit from the development of new therapies.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue the Phase 3 REGAL study of galinpepimut-S (GPS) in AML.
• The interim analysis for the Phase 3 REGAL study is expected in Q4 2024.
• SELLAS will continue the development of SLS009, including the new cohorts in AML with myelodysplasia-related changes.
• The company will report initial safety and efficacy data from the PIVOT program in pediatric tumors throughout 2H 2024.

Key Dates

Keywords

SELLAS Life Sciences, SLS009, Galinpepimut-S, AML, Acute Myeloid Leukemia, Clinical Trial, Phase 3, Phase 2a, Orphan Drug Designation, Rare Pediatric Disease Designation, Capital Raise, IDMC, CDK9 inhibitor, Immunotherapy, Oncology